Latest Stories from Health Promoted Stories,2015-03-21:/category/health2015-03-21T21:31:03-07:00<![CDATA[Macrophage Therapeutics to Expand Efforts Into CNS Diseases]]>,2015-03-20:3651392015-03-20T12:11:08-07:00logo

- Initiative based on data that targeted delivery technology crosses blood brain barrier - ]]>
<![CDATA[Oral OTEZLA® (apremilast) Long-Term Safety and Efficacy Data in Patients with Moderate to Severe Plaque Psoriasis Presented at AAD]]>,2015-03-20:3729062015-03-20T10:00:24-07:00logo

Improvements in the severity of preexisting nail, scalp and palmoplantar psoriasis achieved at week 16 were maintained in OTEZLA responders through week 52 in ESTEEM 2 OTEZLA improved the severity of palmoplantar psoriasis at week 16 in a subset of patients across three trials Long-term safety profile for up to 104 weeks in ESTEEM 1 was consistent with previously reported data from OTEZLA clinical trial programs, with no new safety signals and no clinically meaningful changes in laboratory values ]]>
<![CDATA[Pfizer Announces Oral Tofacitinib Meets Primary Endpoints In Pivotal Phase 3 Psoriasis Trials]]>,2015-03-20:3624942015-03-20T10:00:08-07:00logo

Detailed Results from OPT Pivotal Studies Along with Integrated Analysis of Safety Data from Psoriasis Global Clinical Development Program Presented at 73rd American Academy of Dermatology (AAD) Annual Meeting ]]>
<![CDATA[Innate™ Potato Receives FDA Safety Clearance]]>,2015-03-20:3675962015-03-20T09:01:16-07:00logo

Varieties Contain Beneficial Traits Without Foreign Genes ]]>
<![CDATA[Pernix Therapeutics Inc. to Present at the Deutsche Bank Pharma 1-on-1 Day in Denver, Colorado]]>,2015-03-20:3603142015-03-20T08:33:07-07:00logo

<![CDATA[FDA Approves BIOTRONIK Eluna Pacemaker System with Full-Body ProMRI Technology]]>,2015-03-20:3672872015-03-20T06:29:16-07:00logo

Second Generation Single- and Dual-Chamber Pacemakers That Give Patients Access to MRI Scans Now Available in the U.S. ]]>
<![CDATA[Biogen Idec Presents Positive Interim Results from Phase 1B Study of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) at 2015 AD/PD™ Conference]]>,2015-03-20:3686652015-03-20T02:35:09-07:00logo

– Analysis Demonstrates Acceptable Safety, Statistically Significant Reduction of Amyloid Plaque Levels and Benefit on Exploratory Clinical Endpoints – – Aducanumab Clinical Development Program to Advance to Phase 3 – ]]>
<![CDATA[USDA Adds bioMérieux TEMPO® System to Microbiology Laboratory Guidebook, the Standard-Setting Guideline for Food-Safety Testing in the U.S.]]>,2015-03-19:3607022015-03-19T13:59:01-07:00logo

TEMPO®’s automated food quality testing will help improve food safety nationwide ]]>
<![CDATA[Galderma Announces Positive Phase 3 Trial Results of Investigational Adapalene 0.3%/Benzoyl Peroxide 2.5% (0.3% A/BPO) for the Treatment of Acne]]>,2015-03-19:3620832015-03-19T11:13:09-07:00logo

Pivotal Data to be Presented at This Year’s American Academy of Dermatology Meeting ]]>
<![CDATA[GlycoMimetics to Present First Preclinical Data on E-selectin-CXCR4 Dual Antagonist for Cancer Indications at AACR Annual Meeting 2015]]>,2015-03-19:3695192015-03-19T06:30:16-07:00logo

<![CDATA[Prestium Pharma, Inc. Announces Plans for Release of Improved OLUX® (Clobetasol Propionate) Foam]]>,2015-03-19:3612802015-03-19T05:00:43-07:00logo

Prestium Pharma, Inc. announced it is planning to launch an improved version of OLUX® (clobetasol propionate), 0.05% Foam.]]>
<![CDATA[Svelte Medical Systems Secures Financing; Richard Dakers Joins Board]]>,2015-03-19:3595092015-03-19T04:30:02-07:00logo

All-insider round of investment funds ongoing operations and upcoming commercial activities in Europe. Richard Dakers of the West Health Investment Fund joins the company Board of Directors. ]]>
<![CDATA[CorMatrix® CanGaroo™ Secures International Approval for South America]]>,2015-03-18:3585432015-03-18T12:57:08-07:00logo

CorMatrix Extends Distribution of Its Implantable Device to Buenos Aires Based, Demedic ]]>
<![CDATA[Novan Achieves Target Enrollment for Phase 2 Acne Study]]>,2015-03-18:3574342015-03-18T06:45:09-07:00logo

Company Positioned to Expand Clinical Dermatology Programs in 2015 ]]>
<![CDATA[PsychoGenics Obtains a License to α-synuclein Transgenic Mouse Models of Parkinson´s disease]]>,2015-03-18:3730312015-03-18T05:00:51-07:00logo